These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12102698)

  • 1. Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible?
    Mullins CD; Blak BT; Akhras KS
    Value Health; 2002; 5(4):359-71. PubMed ID: 12102698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
    Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
    J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching.
    Baker TM; Goh J; Johnston A; Falvey H; Brede Y; Brown RE
    J Med Econ; 2012; 15(2):253-60. PubMed ID: 22084957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating patient-centered outcomes in the analysis of cost-effectiveness: imaging strategies for renovascular hypertension.
    Carlos RC; Axelrod DA; Ellis JH; Abrahamse PH; Fendrick AM
    AJR Am J Roentgenol; 2003 Dec; 181(6):1653-61. PubMed ID: 14627591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of hypertension treatment--a review of methodological issues.
    Johannesson M; Jönsson B
    Health Policy; 1991 Sep; 19(1):55-77. PubMed ID: 10117392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
    van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
    Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
    Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential health impact and cost-effectiveness of drug therapy for prehypertension.
    Chen T; Yu D; Cornelius V; Qin R; Cai Y; Jiang Z; Zhao Z
    Int J Cardiol; 2017 Aug; 240():403-408. PubMed ID: 28501349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation.
    Cameron HL; Bernard LM; Garmo VS; Hernandez JB; Asgar AW
    J Med Econ; 2014 Aug; 17(8):599-615. PubMed ID: 24826880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients.
    Cherry SB; Benner JS; Hussein MA; Tang SS; Nichol MB
    Value Health; 2009 Jun; 12(4):489-97. PubMed ID: 18783393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal.
    Kawachi I; Malcolm LA
    J Hypertens; 1991 Mar; 9(3):199-208. PubMed ID: 1851782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.